Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on RNAi therapies for KRAS-driven cancers, has announced agreements for the immediate exercise of outstanding warrants. The exercise involves 2,221,523 ordinary shares at $1.35 per share, expected to generate approximately $3.3 million in gross proceeds.
The company will issue new unregistered warrants to purchase an additional 2,221,523 ordinary shares at $1.50 per share, exercisable immediately upon issuance with a 24-month term. Warrant holders will pay an additional $0.125 per new warrant, contributing $277,690.38 to the gross proceeds. H.C. Wainwright & Co. serves as the exclusive placement agent, and the offering is expected to close around January 30, 2025.
The proceeds will be used as working capital for general corporate purposes. The company will file a registration statement with the SEC for the resale of shares issuable under the new warrants.
Silexion Therapeutics (NASDAQ: SLXN), una biotech in fase clinica focalizzata su terapie RNAi per tumori guidati da KRAS, ha annunciato accordi per l'esercizio immediato di warrant eccellenti. L'esercizio coinvolge 2.221.523 azioni ordinarie a $1,35 per azione, con un'aspettativa di generare circa $3,3 milioni in proventi lordi.
La società emetterà nuovi warrant non registrati per acquistare ulteriori 2.221.523 azioni ordinarie a $1,50 per azione, esercitabili immediatamente al momento dell'emissione con un termine di 24 mesi. I detentori di warrant pagheranno un supplemento di $0,125 per nuovo warrant, contribuendo con $277.690,38 ai proventi lordi. H.C. Wainwright & Co. funge da agente esclusivo per il collocamento e si prevede che l'offerta si chiuda intorno al 30 gennaio 2025.
I proventi saranno utilizzati come capitale di lavoro per esigenze aziendali generali. La società presenterà una domanda di registrazione presso la SEC per la rivendita delle azioni emettibili sotto i nuovi warrant.
Silexion Therapeutics (NASDAQ: SLXN), una biotecnológica en etapa clínica centrada en terapias de RNAi para cánceres impulsados por KRAS, ha anunciado acuerdos para el ejercicio inmediato de warrants pendientes. El ejercicio involucra 2,221,523 acciones ordinarias a $1.35 por acción, con la expectativa de generar aproximadamente $3.3 millones en ingresos brutos.
La compañía emitirá nuevos warrants no registrados para comprar 2,221,523 acciones ordinarias adicionales a $1.50 por acción, ejercitables de inmediato al momento de la emisión con un plazo de 24 meses. Los tenedores de warrants pagarán $0.125 adicionales por cada nuevo warrant, contribuyendo con $277,690.38 a los ingresos brutos. H.C. Wainwright & Co. actúa como agente de colocación exclusivo, y se espera que la oferta se cierre alrededor del 30 de enero de 2025.
Los ingresos se utilizarán como capital de trabajo para fines corporativos generales. La compañía presentará una declaración de registro ante la SEC para la reventa de acciones que se puedan emitir bajo los nuevos warrants.
Silexion Therapeutics (NASDAQ: SLXN)은 KRAS로 유도된 암을 위한 RNAi 치료에 중점을 둔 임상 단계의 생명공학 회사로, 미결제 워런트의 즉각적인 행사에 대한 계약을 발표했습니다. 이 행사는 주당 $1.35의 가격으로 2,221,523주의 보통주를 포함하며, 약 $3.3백만의 총 수익을 창출할 것으로 예상됩니다.
회사는 즉시 행사할 수 있는 새로운 등록되지 않은 워런트를 발행하여 주당 $1.50에 추가로 2,221,523주의 보통주를 구매할 수 있습니다. 워런트 보유자는 새로운 워런트당 추가로 $0.125를 지불하여 $277,690.38를 총 수익에 기여하게 됩니다. H.C. Wainwright & Co.는 독점 배급 에이전트로 활동하며, 이 오퍼링은 2025년 1월 30일경에 마감될 것으로 예상됩니다.
수익은 일반 기업 용도의 운영 자금으로 사용될 것입니다. 회사는 새로운 워런트 아래에서 발행 가능한 주식의 재판매를 위해 SEC에 등록 신고서를 제출할 것입니다.
Silexion Therapeutics (NASDAQ: SLXN), une biotech en phase clinique spécialisée dans les thérapies par RNAi pour les cancers à médiation KRAS, a annoncé des accords pour l'exercice immédiat de warrants en circulation. L'exercice concerne 2.221.523 actions ordinaires à 1,35 $ par action, avec des revenus bruts attendus d'environ 3,3 millions de dollars.
La société émettra de nouveaux warrants non enregistrés pour l'achat de 2.221.523 actions ordinaires supplémentaires à 1,50 $ par action, pouvant être exercés immédiatement après leur émission pour une durée de 24 mois. Les détenteurs de warrants paieront 0,125 $ supplémentaires par nouveau warrant, contribuant ainsi à un total de 277.690,38 $. H.C. Wainwright & Co. agit en tant qu'agent de placement exclusif, et l'offre devrait se clôturer autour du 30 janvier 2025.
Les produits seront utilisés comme fonds de roulement pour des fins d'affaires générales. La société déposera une déclaration d'enregistrement auprès de la SEC pour la revente des actions pouvant être émises sous les nouveaux warrants.
Silexion Therapeutics (NASDAQ: SLXN), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf RNAi-Therapien für KRAS-gesteuerte Krebserkrankungen konzentriert, hat Vereinbarungen für die sofortige Ausübung ausstehender Warrants bekannt gegeben. Die Ausübung betrifft 2.221.523 Stammaktien zu je $1,35, wobei mit einem Bruttoerlös von etwa $3,3 Millionen gerechnet wird.
Das Unternehmen wird neue, nicht registrierte Warrants ausgeben, um zusätzlich 2.221.523 Stammaktien zu einem Preis von $1,50 pro Aktie zu erwerben, die unmittelbar nach der Ausgabe mit einer Laufzeit von 24 Monaten ausgeübt werden können. Die Warrant-Inhaber zahlen zusätzlich $0,125 pro neuem Warrant, was zu einem Bruttoerlös von $277.690,38 beiträgt. H.C. Wainwright & Co. fungiert als exklusive Platzierungsagentur, und das Angebot soll voraussichtlich um den 30. Januar 2025 abgeschlossen werden.
Die Erlöse werden als Betriebskapital für allgemeine Unternehmenszwecke verwendet. Das Unternehmen wird eine Registrierungsanmeldung bei der SEC für den Weiterverkauf von unter den neuen Warrants ausgabefähigen Aktien einreichen.
- Immediate capital raise of $3.3 million through warrant exercise
- New warrants issued with higher exercise price ($1.50 vs $1.35)
- Shares from original warrants are already registered with SEC
- Potential dilution from exercise of 2,221,523 new warrants
- Additional dilution possible if new warrants are exercised
- New warrants currently unregistered, requiring additional SEC filing
Insights
This $3.3M warrant exercise transaction reveals a sophisticated financial engineering approach by Silexion Therapeutics to secure immediate capital while maintaining future upside potential. The structure is particularly noteworthy for several reasons:
The immediate exercise price of
The deal's mechanics are particularly interesting:
- Immediate dilution of approximately
2.1% based on current shares outstanding - Additional potential dilution of
2.1% if new warrants are exercised - Net proceeds will likely be around
$3.0M after fees and expenses
For a clinical-stage biotech with ongoing trials, this capital injection, while modest, provides important working capital. However, the structure suggests possible challenges in securing traditional financing, as warrant exercises typically aren't the first choice for biotech capital raising. The 24-month term on new warrants creates a defined timeline for potential future capital events.
The transaction's legal structure demonstrates sophisticated securities law navigation, balancing immediate capital needs with regulatory compliance. The dual-track approach - using registered shares for immediate exercises while issuing unregistered warrants - minimizes regulatory hurdles while maintaining future flexibility.
Critical legal aspects include:
- Immediate exercises utilize an existing effective S-1 registration
- New warrants issued under Securities Act exemptions require a future registration statement
- Company commits to file a resale registration statement, reducing future trading restrictions
- Structure provides regulatory efficiency while maintaining compliance
The registration commitment for new warrant shares indicates proactive compliance planning, though investors should note potential trading limitations until the resale registration becomes effective. This approach balances immediate execution with future liquidity needs.
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company’s ordinary shares originally issued in January 2025 having an exercise price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
In consideration for the immediate exercise of the warrants for cash and the payment of additional
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants (the “Resale Registration Statement”).
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, the Company is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion’s ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the company, including the proxy statement/prospectus filed with the SEC on July 17, 2024. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets Advisors for Silexion
Arx | Capital Markets Advisors
Capital Raising Desk
silexion@arxadvisory.com
FAQ
How much capital did SLXN raise through the warrant exercise in January 2025?
What is the exercise price of SLXN's new warrants issued in January 2025?
How many new warrants did SLXN issue in the January 2025 transaction?
What is the expiration term for SLXN's new warrants issued in January 2025?
How will SLXN use the proceeds from the January 2025 warrant exercise?
